Compare Nuwellis Inc (NUWE) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Prospect Capital Corporation — how do they compare? Nuwellis Inc trades at $0.8 (market cap $2.50M), while Prospect Capital Corporation trades at $2.19 (market cap $1.13B). The key difference: Prospect Capital Corporation is far larger — about 452× Nuwellis Inc's market cap, and Prospect Capital Corporation pays a 19.09% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NUWE | PSEC | |
|---|---|---|
Market Cap | $2.50M | $1.13B |
Sector | Technology | Financials |
52-Week High | $164.50 | $3.05 |
52-Week Low | $0.73 | $2.11 |
Enterprise Value | -$1.21M | — |
Dividend Yield | — | 19.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.7878, up 0.88% today, but remains in a bearish technical trend. The company shows strong gross margins of 69.69% and double-digit revenue growth, but faces significant profitability challenges with negative net income margins and ROE. Recent developments include a reverse stock split, new CEO appointment, and strategic partnerships expanding pediatric care footprint.
While NUWE demonstrates operational progress with revenue growth and margin improvement, persistent losses and negative cash flow present substantial risk. The mixed analyst sentiment and bearish technical indicators suggest cautious approach. Investment appeal hinges on successful execution of financial efficiency strategy and path to profitability.
Prospect Capital (PSEC) trades at $2.19, down 1.79% recently, with a bearish technical signal and deep discount to book value (P/B 0.39). The company reported negative revenue and net income for 2025, though quarterly EPS has beaten estimates. It maintains a high dividend yield, paying $0.04 monthly, but faces net cash outflow and portfolio contraction concerns highlighted in recent news.
Outlook remains cautious due to financial deterioration and NAV erosion risks, offset by high yield and valuation discount. Analyst consensus is mixed with 25% buy ratings, reflecting divided opinion on recovery potential versus ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
